These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

53 related items for PubMed ID: 9459344

  • 1. Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form.
    Refino CJ, Modi NB, Bullens S, Pater C, Lipari MT, Robarge K, Blackburn B, Beresini M, Weller T, Steiner B, Bunting S.
    Thromb Haemost; 1998 Jan; 79(1):169-76. PubMed ID: 9459344
    [Abstract] [Full Text] [Related]

  • 2. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines.
    Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadváry P, Müller MH, Knopp D, Levet-Trafit B, Lipari MT, Modi NB, Müller M, Refino CJ, Schmitt M, Schönholzer P, Weiss S, Steiner B.
    J Med Chem; 1996 Aug 02; 39(16):3139-47. PubMed ID: 8759635
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers.
    Wittke B, Mackie IJ, Machin SJ, Timm U, Zell M, Goggin T.
    Br J Clin Pharmacol; 1999 May 02; 47(5):521-30. PubMed ID: 10336576
    [Abstract] [Full Text] [Related]

  • 4. SR 121787, a new orally active fibrinogen receptor antagonist.
    Savi P, Badorc A, Lalé A, Bordes MF, Bornia J, Labouret C, Bernat A, de Cointet P, Hoffmann P, Maffrand JP, Herbert JM.
    Thromb Haemost; 1998 Sep 02; 80(3):469-76. PubMed ID: 9759629
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo evaluations of the metabolism, pharmacokinetics, and bioavailability of ester prodrugs of L-767,679, a potent fibrinogen receptor antagonist: an approach for the selection of a prodrug candidate.
    Prueksaritanont T, Gorham LM, Breslin MJ, Hutchinson JH, Hartman GD, Vyas KP, Baillie TA.
    Drug Metab Dispos; 1997 Aug 02; 25(8):978-84. PubMed ID: 9280406
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and pharmacodynamics of sibrafiban (Ro 48-3657), an orally active IIb/IIIa antagonist, administered alone or in combination with heparin, aspirin, and recombinant tissue-type plasminogen activator in beagles.
    Modi NB, Lin YS, Reynolds T, Shaheen A, Christian BJ.
    J Cardiovasc Pharmacol; 1998 Sep 02; 32(3):397-405. PubMed ID: 9733353
    [Abstract] [Full Text] [Related]

  • 7. Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
    Pieniaszek HJ, Sy SK, Ebling W, Fossler MJ, Cain VA, Mondick JT, Ma S, Kornhauser DM.
    J Clin Pharmacol; 2002 Jul 02; 42(7):738-53. PubMed ID: 12092741
    [Abstract] [Full Text] [Related]

  • 8. Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo.
    Herault JP, Peyrou V, Savi P, Bernat A, Herbert JM.
    Thromb Haemost; 1998 Feb 02; 79(2):383-8. PubMed ID: 9493595
    [Abstract] [Full Text] [Related]

  • 9. Non-peptide glycoprotein IIb/IIIa antagonists. 11. Design and in vivo evaluation of 3,4-dihydro-1 (1H)-isoquinolinone-based antagonists and ethyl ester prodrugs.
    Hutchinson JH, Cook JJ, Brashear KM, Breslin MJ, Glass JD, Gould RJ, Halczenko W, Holahan MA, Lynch RJ, Sitko GR, Stranieri MT, Hartman GD.
    J Med Chem; 1996 Nov 08; 39(23):4583-91. PubMed ID: 8917647
    [Abstract] [Full Text] [Related]

  • 10. Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered IIb/IIIa antagonist, in patients with acute coronary syndrome.
    Modi NB, Novotny W, Reimann JD, Cannon CP, Braunwauld E.
    J Clin Pharmacol; 1999 Jul 08; 39(7):675-84. PubMed ID: 10392322
    [Abstract] [Full Text] [Related]

  • 11. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
    Okumura K, Shimazaki T, Aoki Y, Yamashita H, Tanaka E, Banba S, Yazawa K, Kibayashi K, Banno H.
    J Med Chem; 1998 Oct 08; 41(21):4036-52. PubMed ID: 9767641
    [Abstract] [Full Text] [Related]

  • 12. Discovery of novel 2,8-diazaspiro[4.5]decanes as orally active glycoprotein IIb-IIIa antagonists.
    Mehrotra MM, Heath JA, Smyth MS, Pandey A, Rose JW, Seroogy JM, Volkots DL, Nannizzi-Alaimo L, Park GL, Lambing JL, Hollenbach SJ, Scarborough RM.
    J Med Chem; 2004 Apr 08; 47(8):2037-61. PubMed ID: 15056002
    [Abstract] [Full Text] [Related]

  • 13. Disposition of L-738,167, a potent and long-acting fibrinogen receptor antagonist, in dogs. Dose-dependent pharmacokinetics.
    Prueksaritanont T, Gorham LM, Naue JA, Hamill TG, Askew BC, Vyas KP.
    Drug Metab Dispos; 1997 Mar 08; 25(3):355-61. PubMed ID: 9172954
    [Abstract] [Full Text] [Related]

  • 14. Sibrafiban. RO 483657, RO 483657-000, Xubix.
    Drugs R D; 1999 May 08; 1(5):387-9. PubMed ID: 10566072
    [No Abstract] [Full Text] [Related]

  • 15. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist.
    Quinn MJ, Cox D, Foley JB, Fitzgerald DJ.
    J Pharmacol Exp Ther; 2000 Nov 08; 295(2):670-6. PubMed ID: 11046104
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein-IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs.
    Furuya A, Nozawa M, Gotoh J, Jingu S, Akimoto M, Higuchi S, Suwa T, Ogata H.
    J Pharm Pharmacol; 2002 Jul 08; 54(7):921-7. PubMed ID: 12162710
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics and pharmacodynamics of TS-943 for selective nonpeptide platelet glycoprotein IIb/IIIa receptor antagonist in normal healthy subjects.
    Furuya A, Kato N, Jingu S, Akimoto M, Higuchi S, Suwa T, Ogata H.
    Clin Pharmacol Ther; 2000 May 08; 67(5):489-97. PubMed ID: 10824627
    [Abstract] [Full Text] [Related]

  • 18. A population pharmacokinetic-pharmacodynamic and logistic regression analysis of lotrafiban in patients.
    Mould D, Chapelsky M, Aluri J, Swagzdis J, Samuels R, Granett J.
    Clin Pharmacol Ther; 2001 Apr 08; 69(4):210-22. PubMed ID: 11309549
    [Abstract] [Full Text] [Related]

  • 19. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction.
    Lehne G, Nordal KP, Midtvedt K, Goggin T, Brosstad F.
    Thromb Haemost; 1998 Jun 08; 79(6):1119-25. PubMed ID: 9657435
    [Abstract] [Full Text] [Related]

  • 20. Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist.
    Hoffmann P, Bernat A, Savi P, Herbert JM.
    J Pharmacol Exp Ther; 1998 Aug 08; 286(2):670-5. PubMed ID: 9694919
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.